News & Updates

Show Multimedia Only
Poor sleep quality burdens patients with juvenile fibromyalgia syndrome

Poor sleep quality burdens patients with juvenile fibromyalgia syndrome

14 Jun 2023

Patients with juvenile fibromyalgia syndrome (JFS) often complain of sleep problems, which have a significant impact on clinical domains of the disease, including depression and pain, reports a study.

Poor sleep quality burdens patients with juvenile fibromyalgia syndrome

14 Jun 2023
Depression, anxiety symptoms saddle adolescents with JIA

Depression, anxiety symptoms saddle adolescents with JIA

13 Jun 2023

Adolescents with juvenile idiopathic arthritis (JIA) remain vulnerable to symptoms of depression and anxiety, particularly panic, according to a study, noting the ongoing need for mental health screening protocols and services in this population.

Depression, anxiety symptoms saddle adolescents with JIA

13 Jun 2023
Brepocitinib doses hold promise in treatment of psoriatic arthritis

Brepocitinib doses hold promise in treatment of psoriatic arthritis

26 May 2023
Which COVID-19 vaccine should SARDs patients on immunomodulators use?

Which COVID-19 vaccine should SARDs patients on immunomodulators use?

26 May 2023
Fibromyalgia symptoms weakly predict RA activity after treatment

Fibromyalgia symptoms weakly predict RA activity after treatment

24 May 2023

Higher levels of fibromyalgia (FM) symptoms in patients with rheumatoid arthritis (RA) are slightly indicative of worse disease activity following treatment with a disease-modifying antirheumatic drug (DMARD), suggest the results a recent study.

Fibromyalgia symptoms weakly predict RA activity after treatment

24 May 2023
Sarcoidosis not uncommon in systemic sclerosis

Sarcoidosis not uncommon in systemic sclerosis

23 May 2023

The occurrence of sarcoidosis in patients with systemic sclerosis (SSc) is rare but seems to be more frequent when compared to the general population, reveals a study.

Sarcoidosis not uncommon in systemic sclerosis

23 May 2023
Selective autotaxin inhibition shows promise in diffuse cutaneous systemic sclerosis

Selective autotaxin inhibition shows promise in diffuse cutaneous systemic sclerosis

23 May 2023

The selective autotaxin inhibitor ziritaxestat shows therapeutic potential in patients with early diffuse cutaneous systemic sclerosis, conferring greater reductions in modified Rodnan skin score compared with placebo and potentially reducing fibrosis, according to data from the phase IIa NOVESA study.

Selective autotaxin inhibition shows promise in diffuse cutaneous systemic sclerosis

23 May 2023
Rheumatologists need to match patient’s health literacy, says study

Rheumatologists need to match patient’s health literacy, says study

22 May 2023

Communication between physicians and patients with systemic lupus erythematosus (SLE) leaves a lot to be desired, with a recent study suggesting that rheumatologists must beef up communication to match the health literacy (HL) of their patients. Doing so may foster trust and improve self-management and outcomes in SLE.

Rheumatologists need to match patient’s health literacy, says study

22 May 2023